Flyer

International Journal of Drug Development and Research

  • ISSN: 0975-9344
  • Journal h-index: 49
  • Journal CiteScore: 11.20
  • Journal Impact Factor: 8.24
  • Average acceptance to publication time (5-7 days)
  • Average article processing time (30-45 days) Less than 5 volumes 30 days
    8 - 9 volumes 40 days
    10 and more volumes 45 days
Awards Nomination 20+ Million Readerbase
Indexed In
  • Genamics JournalSeek
  • China National Knowledge Infrastructure (CNKI)
  • CiteFactor
  • Scimago
  • Directory of Research Journal Indexing (DRJI)
  • OCLC- WorldCat
  • Publons
  • MIAR
  • University Grants Commission
  • Euro Pub
  • Google Scholar
  • J-Gate
  • SHERPA ROMEO
  • Secret Search Engine Labs
  • ResearchGate
  • International Committee of Medical Journal Editors (ICMJE)
Share This Page

Abstract

HPLC method for the simultaneous determination of Levocetirizine, Ambroxol and Montelukast in human Plasma employing response Surface Methodology

Ramalingam Suresh, Rajappan Manavalan and Kannappan Valliappan

Multiple response simultaneous optimizations employing the Derringer’s desirability function for the development of reversed-phase HPLC methods for the simultaneous determination of Ambroxol(AMB) and Montelukast(MLS) with Levocetirizine (LCT) and Probenecid(PRO) as Internal standard in human plasma samples is described. The ranges of the independent variables used for the optimization were MeCN: 30-40%, buffer conc.: 10-20 mM and flow rate: 0.8-1.2 ml/min. The influence of these independent variables on the output responses: capacity factor of the first peak (k1), resolutions (Rs2,3), and Retention time (tR4) were evaluated. Using this strategy, mathematical model were defined and response surface were derived for the separation. The coefficient of determination R2 was more than 0.8972 for all the models. The three responses were simultaneously optimized by using Derringer’s desirability functions. Optimum conditions chosen for assay were MeCN, MeOH, 20.00 mM K2HPO4 (pH 7.0 ± 0.5) solution (32.7:30: 37.3 v/v/v) and flow rate 0.85 ml/min. The eluate was monitored using an UV detector set at 230 nm. Peak area ratio of the analyte and internal standard was used for the quantification of plasma samples. Total chromatographic analysis time per sample was approximately 8.665 min. The validation of the proposed analytical method was conducted in accordance to the recommendations of the guidelines ‘‘Bioanalytical method validation’’ [FDA-CDER, 2001]. The method was found to be simple, sensitive and hence it could be applied in bioavailability studies.